Pharma Should Factor Medication Adherence Into Drug Development
New Strategic Insights Report on Costly Patient Nonadherence Now Available from Decision Resources
BURLINGTON, Mass., Dec. 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process. Medication adherence is a combination of correct use of a medication and persistence (continuing to use medication as prescribed). It is a challenging issue in healthcare with an estimated 75 percent of prescription drug consumers in the United States alone reporting some form of medication nonadherence.
In its new Strategic Insights report entitled, The $300 Billion Elephant: Strategies for Addressing Patient Nonadherence , Decision Resources finds that reminder packaging is a consistently effective medication adherence intervention strategy. Thus, particular attention should be paid early in a drug's development to packaging and information inserts that will help patients better adhere to their prescribed medication. Additionally, a focus on minimizing side effects and rapid, durable efficacy will likely help yield greater adherence rates post-launch.
"In competitive chronic disease treatment markets, early positioning of a new brand based on superior adherence could be a strong differentiator in a crowded market," said Decision Resources Group Senior Vice President Kate Hohenberg.
About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com
SOURCE Decision Resources
Web Site: http://www.decisionresources.com
BURLINGTON, Mass., Dec. 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process. Medication adherence is a combination of correct use of a medication and persistence (continuing to use medication as prescribed). It is a challenging issue in healthcare with an estimated 75 percent of prescription drug consumers in the United States alone reporting some form of medication nonadherence.
In its new Strategic Insights report entitled, The $300 Billion Elephant: Strategies for Addressing Patient Nonadherence , Decision Resources finds that reminder packaging is a consistently effective medication adherence intervention strategy. Thus, particular attention should be paid early in a drug's development to packaging and information inserts that will help patients better adhere to their prescribed medication. Additionally, a focus on minimizing side effects and rapid, durable efficacy will likely help yield greater adherence rates post-launch.
"In competitive chronic disease treatment markets, early positioning of a new brand based on superior adherence could be a strong differentiator in a crowded market," said Decision Resources Group Senior Vice President Kate Hohenberg.
About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com
SOURCE Decision Resources
Web Site: http://www.decisionresources.com
.png)
No hay comentarios:
Publicar un comentario